However, a new population-wide study being presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept) finds that half of adults without diabetes who start taking the weight-loss drug semaglutide in Denmark discontinue treatment within a year. Similarly, users living in low-income areas were 14% more likely to discontinue treatment within the first year than those living in high-income areas. The study also found that men were 12% more likely to stop treatment within a year than women, which might reflect unsatisfactory weight loss given the better weight loss outcomes generally observed in women taking GLP-1RAs than men. Finally, the researchers did not have information on the amount of weight loss achieved after semaglutide initiation. Reference:Half of people stop taking popular weight-loss drug within a year, national study finds, European Association for the Study of Diabetes, Meeting: Annual Meeting of the European Association for the Study of Diabetes (EASD).